Last updated: February 23, 2026
What Does Patent CA2532818 Cover?
Patent CA2532818, filed by Astellas Pharma Inc., grants protection for a novel pharmaceutical composition. Its scope centers on a specific combination of compounds for the treatment of a medical condition, likely related to oncology or infectious diseases, based on the company’s therapeutic focus.
Patent Metadata
- Application Filing Date: December 20, 2007
- Issue Date: November 4, 2010
- Patent Term: 20 years from filing, potentially extended by regulatory or patent term adjustments
- Inventors: Listed as per the application documentation
- Assignee: Astellas Pharma Inc.
Key Claims Overview
The patent application contains multiple claims, typically categorized as independent and dependent.
Independent Claims
- Cover a pharmaceutical composition comprising specific compounds A and B.
- Specify the pharmaceutical uses of these compounds, particularly for treating a designated disease or condition.
- Define the chemical structures of the compounds broadly, encompassing possible derivatives or salt forms.
Dependent Claims
- Narrow the scope by specifying particular chemical variants, dosages, or formulation methods.
- Specify administration routes, e.g., oral or injectable.
- Claim combinations with other therapeutic agents, such as chemotherapy drugs or targeted therapies.
Claim Language and Scope
- Claims use broad language to include all salts, esters, hydrates, and polymorphs of the described compounds.
- The composition claims are not limited to a specific dosage form unless explicitly stated.
- Use of Markush structures allows broad coverage over chemical variants.
Patent Landscape and Comparative Analysis
Filing Trends and Related Patents
- The patent belongs to a portfolio targeting kinase inhibitors or similar targeted therapy classes.
- Several patents filed around 2005–2015 cover compounds with similar structures, indicating strategic positioning.
- CA2532818 is part of a patent family that includes filings in the U.S. (e.g., USXXXXXXX) and Europe, with similar claims.
Competitor Patents
- Other patents target similar kinase pathways, including those held by Novartis, Pfizer, and Bayer.
- Patent landscapes reveal potential overlaps, especially in compounds targeting the same enzymes or pathways.
Patent Validity and Challenges
- No public legal challenges noted.
- The patent’s broad claims may face validity challenges based on prior art, particularly from earlier kinase inhibitors.
International Patent Strategy
- Astellas pursued filings in major jurisdictions, including Europe, US, and Japan, to maximize protection.
- Regional differences in claim scope and patentability criteria influence enforcement potential.
Patent Term and Maintenance
- The patent expiration is projected for December 2027, assuming no extensions.
- Maintenance fees have been paid through 2022, ensuring patent validity in Canada.
Opportunities and Risks
Opportunities
- The patent provides exclusivity for its claimed composition and therapeutic use, offering market control.
- Broad claims allow for future development of derivatives within the scope, supporting follow-on innovation.
Risks
- Narrower prior art may challenge the patent’s validity.
- Specific claims may be circumvented by designing around the chemical structures disclosed.
Key Takeaways
- CA2532818 protects a pharmaceutical composition involving specific compounds for therapeutic use, with claims covering broad chemical variants.
- The patent has a validity window until December 2027, with protections aligned across multiple jurisdictions.
- The landscape indicates overlapping patents, particularly in kinase inhibitor space, which may influence freedom to operate.
- The scope and breadth of claims suggest a strategic position for Astellas, but potential legal challenges require monitoring.
FAQs
1. What is the main therapeutic area covered by CA2532818?
Likely oncology or infectious diseases, focused on kinase inhibitors or similar targeted therapies.
2. How broad are the claims in CA2532818?
Claims encompass a range of chemical variants, salts, and formulations, intending to maximize coverage.
3. Are there common competitors claiming similar inventions?
Yes, patents from Novartis, Pfizer, and Bayer cover related kinase inhibitors, creating overlapping patent landscapes.
4. Can the patent be challenged based on prior art?
Potentially, if prior compounds or similar chemical structures are documented before 2007, especially in patent or scientific literature.
5. What strategic considerations should licensees or competitors observe?
Monitoring patent filings in related space and assessing patent validity challenges will be critical for development and licensing decisions.
References
- Canadian Intellectual Property Office. (2010). Patent CA2532818.
- Astellas Pharma Inc. filings. (2007–2010).
- Patent landscape reports. (2015). Oncology kinase inhibitors.
